External Counterpulsation Treatment (ECP – EECP Therapy)

ECP EECP treatment

ECP provides an opportunity to treat and improve the quality of life for cardiac patients who are refractory to medications and are not candidates for surgical revascularization. This non-invasive treatment for heart disease requires approximately 35 one-hour sessions administered 5 days a week for the duration of 7 weeks.

The Heart Fit Clinic is offering this treatment.

Please contact us for more information regarding our ECP program.

ECP Calgary EECP Calgary
ECP Alberta EECP Alberta
ECP Canada EECP Canada

 

 

 

 

 

Are You Looking For Improved Circulation?

External Counterpulsation (ECP/EECP) Therapy

 

  • — -Safe
  • — -Painless
  • — -Non-invasive
  • — -No Radiation
  • — -No Surgery
  • — -No Medications



WHO IS ECP  – EECP  FOR?

  1. Patients who are taking angina medication
  2. Heart failure.
  3. Restenosis
  4. Patients not amenable to stent or bypass.
  5. Microvascular disease
  6. Poor Endothelial function or coronary spasm



US FDA approved for the treatment of:

  • — -Angina                      —
  •  -Congestive Heart Failure
  • — -Cardiogenic Shock    —
  •  -Acute Myocardial Infarction



HOW DOES IT WORK?
The ECP treatment is one hour treatments, 5 days a week for 7 weeks. During treatment, blood pressure cuffs are wrapped around the legs are then inflated and deflated in sync with your heartbeat. This results in a massive increase of blood flow throughout your body and improving collateral circulation in your heart.  Tiny blood vessels help increase and normalize blood flow to the heart muscle.

External Counterpulsation ECP EECP flow


BENEFITS:
It helps increased blood flow and creates a natural bypass in the heart.
Patients report:

  • – – Increases energy and stamina
  • – – Reduces or eliminates angina
  •  – Return to activities they thought they had given up forever
  •  – Ability to rest and sleep better.
  •  – It helps improve blood flow therefore has also shown to help people with diabetes, peripheral vascular disease, and high blood pressure.
  •  – As it improves endothelial function it can improve erectile dysfunction.



CONTRAINDICATION

ECP is not for everyone. Here are a list of contraindication for therapy:

  • -Arrythmias (uncontrolled atrial arrhythmias, or very frequent ectopy per minute).
  • -Sinus Tachycardia ( >110 beats per minute)
  • -Bleeding diathesis
  • -Active thrombephlebetis
  • -Hemorrhagic disease
  • -Aortic aneurysm, dissection or ileofermoral artery obstruction.
  • -Pregnancy
  • -Severe Hypertension (>180/110)
  • -Severe valvular disease



CLINICAL EVIDENCE

ECP/EECP is completed all over the World including the Mayo and Cleveland Clinics. It has undergone clinical trials at leading universities around the nation and been subject to over a hundred scientific studies published in the most prestigious medical journals throughout the World.
Clinical trials have shown ECP therapy to be safe and effective for patients with heart disease with a clinical response rate averaging 80%, which is sustained up to five years. ECP is a great non-invasive alternative to intervention. For more information on research: www.externalcounterpulsation.ca/research-ecp-eecp/

There is evidence demonstrating improved endothelial function via the hemodynamic effects by the increased shear stress acting on the arterial wall, reducing arterial stiffness and providing protective effects against inflammation, inhibiting intimal hyperplasia and the atherosclerotic process.


ECP most recent mentions:


January 2014
External Counterpulsation Therapy has been reclassified by the Food & Drug Administration for severe Angina not amendable to surgery. This comes as big news to the External Counterpulsation Therapy industry as the ECP and EECP devices have been categorized as a higher class device. The U.S. Food and Drug Administration (FDA), Department of Health and Human Services, issued its final decision to reclassify ECP Therapy Devices for treatment of chronic stable angina for patients that are refractory to anti-anginal medical therapy and without options for revascularization.

 


December 2013
EECP (Enhanced External Counterpulsation Therapy) is given Recommendation in the 2013 European Society of Cardiology (ESC) Guidelines on the Management of Stable Coronary Artery Disease (SCAD). The guidelines were released during ESC’s annual meeting which took place from August 31 to September 3, 2013 in Amsterdam, the Netherlands.


BLOOD FLOW ADVANTAGES

  • -Increases Venous Return
  • -Increases Cardiac Output
  • -Reduces Systolic Pressure (Ventricular Unloading)
  • -Increases Myocardial Perfusion
  • -Decreases Oxygen Demand
  • -Increases Oxygen Utilization



ECP is very unique because its mode of action is on the smaller vessels in the heart, which are too small for bypass surgery or angioplasty. The treatment works in different area of the blood circulation where Bypass surgery and Angioplasty cannot access. Cardiothoracic surgeon and Invasive cardiologist can use the treatment as an adjuvant to their standard interventional procedure. Therefore we can treat patients with chest pain and poor exercise tolerance who have reached maximal medication.

Neuro-hormone Benefits Objective Measures Clinical Outcomes
  • Increased nitric oxide levels
  • Decrease endothelin levels
  • Decrease rennin- Angiotensin levels
  • Decrease BNP Levels
  • Increase VEGF levels

 

  • Increase time to ST- segment depression
  • Increase exercise tolerance
  • Improve myocardial perfusion assessed by thallium/MIBI /PET
  • Increase ejection fraction and cardiac output
  • Decrease Peripheral vascular resistance.
    Improvement in peak oxygen consumption.
  • Improvement in angina and anginal equivalent
  • Reduce in use of nitrate
  • Improved quality of life
  • Long term sustained clinical benefit up to 5 years
  • Improvement in angina and anginal equivalent
  • Reduce in use of nitrate
  • Improved quality of life
  • Long term sustained clinical benefit up to 5 years

 

 

pastedGraphic_2_-530x471

 



RESEARCH ECP Trials

 

  • Michaels, A. D. et al. Primer: practical approach to the selection of patients for and application of EECP. Nat. Clin. Pract. Cardiovasc. Med. 3, 623–632 (2006).
  • Sinvhal, R. M., Gowda, R. M. & Khan, I. A. Enhanced external counterpulsation for refractory angina pectoris. Heart 89, 830–833 (2003).
  • Braith, R. W. et al. Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study. Circulation 122, 1612–1620 (2010).
  • Bonetti, P. O. et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J. Am. Coll. Cardiol. 41, 1761–1768 (2003).
  • Michaels, A. D. et al. The effects of enhanced external counterpulsation on myocardial perfusion in patients with stable angina: a multicenter radionuclide study. Am. Heart J. 150, 1066–1073 (2005).
  • Akhtar, M., Wu, G. F., Du, Z. M., Zheng, Z. S. & Michaels, A. D. Effect of external counterpulsation on plasma nitric oxide and endothelin-1 levels. Am. J. Cardiol. 98, 28–30 (2006).
  • Kiernan, T. J. et al. Effect of enhanced external counterpulsation on circulating CD34+ progenitor cell subsets. Int. J. Cardiol. 153, 202–206 (2011).
  • Campbell, A. R. et al. Enhanced external counterpulsation improves systolic blood pressure in patients with refractory angina. Am. Heart J. 156, 1217–1222 (2008).
  • Arora, R. R. et al. The multicenter study of enhanced external counterpulsation (MUST- EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J. Am. Coll. Cardiol. 33, 1833–1840 (1999).

 

Please contact us for more information regarding our ECP program.

ECP Calgary EECP Calgary
ECP Alberta EECP Alberta
ECP Canada EECP Canada

 

img img img
img img